Screener
Intellia Therapeutics NTLA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $11,714 | $20,252 |
| Accrued expenses | 44,334 | 49,862 |
| Current portion of operating lease liability | 23,344 | 26,480 |
| Current portion of deferred revenue | - | 7,290 |
| Total current liabilities | 79,392 | 103,884 |
| Long-term operating lease liability | 50,066 | 66,849 |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's accrued expenses?
- Intellia Therapeutics (NTLA) reported accrued expenses of $44.33M in Q2 2026.
- How has Intellia Therapeutics's accrued expenses changed year-over-year?
- Intellia Therapeutics's accrued expenses increased by 6.7% year-over-year, from $41.55M to $44.33M.
- What is the long-term trend for Intellia Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Intellia Therapeutics's accrued expenses has grown at a 14.3% compound annual growth rate (CAGR), from $25.55M to $49.86M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Intellia Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude